NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer

NCT ID: NCT01521702


Title
Adjuvant Gemcitabine Versus NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer: a Randomized Multicenter Phase III Study
Purpose
The aim of this study is to test the additional value of neoadjuvant chemotherapy to the standard treatment for resectable pancreatic cancer (surgery + adjuvant chemotherapy). This study will be performed in compliance with the study protocol, GCP (good clinical practice) and the applicable regulatory requirements.
Details
Conditions
Pancreas Cancer
Keywords
adenocarcinoma, pancreatic head
Source
Institut Paoli-Calmettes
Sponsors
Institut Paoli-Calmettes
Status
Completed
Acronym
NEOPAC
Last Updated
18 Mar 2015
URL
Official Link
Locations
France